title: Diagnosis and clinical characteristics of inherited activated protein C resistance.
abstract: The diagnostic strategies and clinical characteristics of thrombophilia associated with heterozygous or homozygous factor V Leiden mutation have been determined according to the literature and to a personal study in 51 families. Factor V mutation was present in the 51 propositi and in 84 out of 125 family members (81 heterozygous, 3 homozygous). Venous thrombosis was observed in all the propositi, in 17 of the 84 family members with the mutation and in 6 of the 41 with a normal APC resistance test and no mutation. An associated protein C or protein S deficiency was present in 5 families (10%). The most frequent clinical manifestations were superficial or deep vein thrombosis and/or pulmonary embolism, but also thrombosis at an unusual site (cerebral, mesenteric or central retinal vein). A causal relationship is frequently difficult to demonstrate. A precipitating factor was observed in 84% of cases and a recurrent thrombotic episode occurred in 50% of propositi. The risk of thrombosis associated with pregnancy was high in the post-partum period, especially in homozygous women. In the 28 homozygous subjects, markers of coagulation activation were frequently elevated in untreated patients. Finally, the efficacy of anticoagulant treatment is suggested but the long period often observed between treatment interruption and a recurrence does not militate in favour of long term treatment.
authors.affiliation: Service d'Hématologie Biologique, Hôtel-Dieu, Paris, France.
authors.forename: M M
authors.initials: MM
authors.lastname: Samama
authors.forename: D
authors.initials: D
authors.lastname: Simon
authors.forename: M H
authors.initials: MH
authors.lastname: Horellou
authors.forename: M
authors.initials: M
authors.lastname: Trossaërt
authors.forename: I
authors.initials: I
authors.lastname: Elalamy
authors.forename: J
authors.initials: J
authors.lastname: Conard
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D004252:DNA Mutational Analysis; D004789:Enzyme Activation; D005165:Factor V / Q000032:analysis*; D005166:Factor V Deficiency / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D011237:Predictive Value of Tests; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology; D011486:Protein C / Q000502:physiology*; D018455:Protein S Deficiency / Q000150:complications; D011644:Puerperal Disorders / Q000188:drug therapy / Q000453:epidemiology; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D012008:Recurrence; D012307:Risk Factors; D013924:Thrombophlebitis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D003278:Contraceptives, Oral, Hormonal; D011486:Protein C; C095381:factor V Leiden; D005165:Factor V